Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN

ME. Joosse, MA. Aardoom, P. Kemos, D. Turner, DC. Wilson, S. Koletzko, J. Martin-de-Carpi, UL. Fagerberg, C. Spray, C. Tzivinikos, M. Sladek, R. Shaoul, E. Roma-Giannikou, J. Bronsky, DE. Serban, FM. Ruemmele, H. Garnier-Lengline, G. Veres, I....

. 2018 ; 48 (5) : 523-537. [pub] 20180708

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035138

Grantová podpora
G0800675 Medical Research Council - United Kingdom

E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 18 měsíci
Medline Complete (EBSCOhost) od 1998-01-01 do Před 1 rokem
Wiley Free Content od 1997 do Před 18 měsíci

BACKGROUND: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to their rare occurrence. AIM: To identify and describe the most common causes of mortality, types of cancer and previous or current therapy among children and young adults with paediatric-onset IBD. METHODS: Information on paediatric-onset IBD patients diagnosed with malignancy or mortality was prospectively collected via a survey in 25 countries over a 42-month period. Patients were included if death or malignancy occurred after IBD diagnosis but before the age of 26 years. RESULTS: In total, 60 patients were identified including 43 malignancies and 26 fatal cases (9 due to cancer). Main causes of fatality were malignancies (n = 9), IBD or IBD-therapy related nonmalignant causes (n = 10; including 5 infections), and suicides (n = 3). Three cases, all fatal, of hepatosplenic T-cell lymphoma were identified, all were biologic-naïve but thiopurine-exposed. No other haematological malignancies were fatal. The 6 other fatal cancer cases included 3 colorectal adenocarcinomas and 3 cholangiocarcinomas (CCAs). Primary sclerosing cholangitis (PSC) was present in 5 (56%) fatal cancers (1 colorectal carcinoma, 3 CCAs and 1 hepatosplenic T-cell lymphoma). CONCLUSIONS: We report the largest number of paediatric-onset IBD patients with cancer and/or fatal outcomes to date. Malignancies followed by infections were the major causes of mortality. We identified PSC as a significant risk factor for cancer-associated mortality. Disease-related adenocarcinomas were a commoner cause of death than lymphomas.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035138
003      
CZ-PrNML
005      
20191010094234.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/apt.14893 $2 doi
035    __
$a (PubMed)29984520
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Joosse, M E $u Rotterdam, The Netherlands.
245    10
$a Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN / $c ME. Joosse, MA. Aardoom, P. Kemos, D. Turner, DC. Wilson, S. Koletzko, J. Martin-de-Carpi, UL. Fagerberg, C. Spray, C. Tzivinikos, M. Sladek, R. Shaoul, E. Roma-Giannikou, J. Bronsky, DE. Serban, FM. Ruemmele, H. Garnier-Lengline, G. Veres, I. Hojsak, KL. Kolho, IH. Davies, M. Aloi, P. Lionetti, S. Hussey, G. Veereman, CP. Braegger, E. Trindade, AV. Wewer, AC. Hauer, ACH. de Vries, R. Sigall Boneh, C. Sarbagili Shabat, A. Levine, L. de Ridder, Paediatric IBD Porto group of ESPGHAN,
520    9_
$a BACKGROUND: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to their rare occurrence. AIM: To identify and describe the most common causes of mortality, types of cancer and previous or current therapy among children and young adults with paediatric-onset IBD. METHODS: Information on paediatric-onset IBD patients diagnosed with malignancy or mortality was prospectively collected via a survey in 25 countries over a 42-month period. Patients were included if death or malignancy occurred after IBD diagnosis but before the age of 26 years. RESULTS: In total, 60 patients were identified including 43 malignancies and 26 fatal cases (9 due to cancer). Main causes of fatality were malignancies (n = 9), IBD or IBD-therapy related nonmalignant causes (n = 10; including 5 infections), and suicides (n = 3). Three cases, all fatal, of hepatosplenic T-cell lymphoma were identified, all were biologic-naïve but thiopurine-exposed. No other haematological malignancies were fatal. The 6 other fatal cancer cases included 3 colorectal adenocarcinomas and 3 cholangiocarcinomas (CCAs). Primary sclerosing cholangitis (PSC) was present in 5 (56%) fatal cancers (1 colorectal carcinoma, 3 CCAs and 1 hepatosplenic T-cell lymphoma). CONCLUSIONS: We report the largest number of paediatric-onset IBD patients with cancer and/or fatal outcomes to date. Malignancies followed by infections were the major causes of mortality. We identified PSC as a significant risk factor for cancer-associated mortality. Disease-related adenocarcinomas were a commoner cause of death than lymphomas.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a věk při počátku nemoci $7 D017668
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a idiopatické střevní záněty $x komplikace $x epidemiologie $x mortalita $7 D015212
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory $x komplikace $x epidemiologie $x mortalita $7 D009369
650    _2
$a prospektivní studie $7 D011446
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Aardoom, M A $u Rotterdam, The Netherlands.
700    1_
$a Kemos, P $u London, UK.
700    1_
$a Turner, D $u Jerusalem, Israel.
700    1_
$a Wilson, D C $u Edinburgh, UK.
700    1_
$a Koletzko, S $u Munich, Germany.
700    1_
$a Martin-de-Carpi, J $u Barcelona, Spain.
700    1_
$a Fagerberg, U L $u Stockholm, Sweden.
700    1_
$a Spray, C $u Bristol, UK.
700    1_
$a Tzivinikos, C $u Dubai, United Arab Emirates.
700    1_
$a Sladek, M $u Cracow, Poland.
700    1_
$a Shaoul, R $u Haifa, Israel.
700    1_
$a Roma-Giannikou, E $u Athens, Greece.
700    1_
$a Bronsky, J $u Prague, Czech Republic.
700    1_
$a Serban, D E $u Cluj-Napoca, Romania.
700    1_
$a Ruemmele, F M $u Paris, France.
700    1_
$a Garnier-Lengline, H $u Paris, France.
700    1_
$a Veres, G $u Budapest, Hungary.
700    1_
$a Hojsak, I $u Zagreb, Croatia.
700    1_
$a Kolho, K L $u Helsinki, Finland. Tampere, Finland.
700    1_
$a Davies, I H $u Cardiff, UK.
700    1_
$a Aloi, M $u Rome, Italy.
700    1_
$a Lionetti, P $u Florence, Italy.
700    1_
$a Hussey, S $u Dublin, Ireland.
700    1_
$a Veereman, G $u Brussels, Belgium.
700    1_
$a Braegger, C P $u Zurich, Switzerland.
700    1_
$a Trindade, E $u Porto, Portugal.
700    1_
$a Wewer, A V $u Hvidovre, Denmark.
700    1_
$a Hauer, A C $u Graz, Austria.
700    1_
$a de Vries, A C H $u Rotterdam, The Netherlands.
700    1_
$a Sigall Boneh, R $u Tel-Aviv, Israel.
700    1_
$a Sarbagili Shabat, C $u Tel-Aviv, Israel.
700    1_
$a Levine, A $u Tel-Aviv, Israel.
700    1_
$a de Ridder, L $u Rotterdam, The Netherlands.
710    2_
$a Paediatric IBD Porto group of ESPGHAN
773    0_
$w MED00009085 $t Alimentary pharmacology & therapeutics $x 1365-2036 $g Roč. 48, č. 5 (2018), s. 523-537
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29984520 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191010094652 $b ABA008
999    __
$a ok $b bmc $g 1451798 $s 1073688
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 48 $c 5 $d 523-537 $e 20180708 $i 1365-2036 $m Alimentary pharmacology & therapeutics $n Aliment Pharmacol Ther $x MED00009085
GRA    __
$a G0800675 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...